FLHLF - Filament Health starts dosing in its FDA-approved psilocin clinical trial
- Filament Health ( OTC:FLHLF ) on Thursday said it had started dosing in its FDA-approved trial to evaluate its psychedelic drug candidates.
- FLHLF said the phase 1 trial would be the first to administer psilocin and psilocybin directly derived from magic mushrooms, instead of being synthesized in the lab.
- The trial would evaluate three of the psychedelic drug company's investigational botanical candidates that are stabilized forms of the psychedelic compounds from certain mushrooms.
- The goal of the trial would be to compare the effects of psilocin and psilocybin administered in different ways to healthy adults.
For further details see:
Filament Health starts dosing in its FDA-approved psilocin clinical trial